SBI Securities’s Akari Therapeutics AKTX Stock Holding History

SBI Securities’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$140	Buy	15 +1	+7%	+$10	﹤0.01%	3501
2026 Q2	$143	Buy	14 +9	+180%	+$78	﹤0.01%	3419
2026 Q1	$26	Hold	5	–	–	﹤0.01%	3706
2025 Q4	$58	Buy	+5	New	+$116	﹤0.01%	3545
2025 Q1	–	Hold	0	–	-$6	–	4127
2024 Q4	–	Hold	0	–	–	–	3969

Other funds holding AKTX

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Occidental Asset Management Burlingame, California $1.16B AUM 26.15% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.52B AUM 24.83% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

SBI Securities's AKTX Position: Q3 2026 in Review

SBI Securities increased its Akari Therapeutics (AKTX) stake by 7.1% in Q3 2026, buying an estimated $10 and bringing the position to 15 shares worth $140. The position accounts for ﹤0.01% of the portfolio, ranked #3501.

SBI Securities first reported a position in AKTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $143 in Q2 2026. 8 funds tracked by Wall St. Rank hold AKTX as of Q3 2026.

SBI Securities held 15 shares of Akari Therapeutics worth $140 as of Q3 2026.
SBI Securities bought 1 Akari Therapeutics share in Q3 2026, an estimated $10.
Akari Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3501 holding.
SBI Securities first reported a position in Akari Therapeutics in Q4 2025 and has held it in 4 quarters since.
SBI Securities's Akari Therapeutics position peaked at $143 in Q2 2026.
8 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.